If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
== External links == Mass spectrometry characterization of human ACTC1 at COPaKB GeneReviews/NIH/NCBI/UW entry on Familial Hypertrophic Cardiomyopathy Overview Human ACTC1 genome location and ACTC1 gene details page in the UCSC Genome Browser.
Pathogenic bacteria are bacteria that can cause disease. This article focuses on the bacteria that are pathogenic to humans. Most species of bacteria are harmless and many are beneficial but others can cause infectious diseases. The number of these pathogenic species in humans is estimated to be fewer than a hundred. By contrast, several thousand species are considered part of the gut flora, with a few hundred species present in each individual human's digestive tract. The body is continually exposed to many species of bacteria, including beneficial commensals, which grow on the skin and mucous membranes, and saprophytes, which grow mainly in the soil and in decaying matter. The blood and tissue fluids contain nutrients sufficient to sustain the growth of many bacteria. The body has defence mechanisms that enable it to resist microbial invasion of its tissues and give it a natural immunity or innate resistance against many microorganisms. Pathogenic bacteria are specially adapted and endowed with mechanisms for overcoming the normal body defences, and can invade parts of the body, such as the blood, where bacteria are not normally found. Some pathogens invade only the surface epithelium, skin or mucous membrane, but many travel more deeply, spreading through the tissues and disseminating by the lymphatic and blood streams.
Built in the Interwar period, it is now the largest in Seine-Maritime with about 1,300 moorings additional moorings were installed in the Vauban basin in 2011–2012. The Havraise Rowing Society has trained many rowers to a high level as Thierry Renault. The Club Nautique Le Havrais (CNH) is the centre of mixed swimming, synchronized swimming, and men's water polo. The Centre Nautique Paul Vatine is the fifth largest club in the country for the number of sports licenses it holds; it ranks second in the Division 1 of the Championship France for Catamaran Clubs. Several major local sportsmen began their career at Le Havre: the swimmer Hugues Duboscq was an Olympic medallist several times. In judo the French team has two members from Le Havre: Dimitri Dragin and Baptiste Leroy. Jerome Le Banner is a professional kick-boxer at world level who participates in the K-1 championship. Finally the navigator Paul Vatine, who was lost at sea in 1999, won the Transat Jacques Vabre several times.
Sources: en.wikipedia.org
=== Halides === Protactinium(V) fluoride is a white compound that forms tetragonal crystals, isomorphic to β-UF5. Protactinium(V) chloride forms yellow crystals where protactinium ions are arranged in pentagonal bipyramids and coordinated by 7 other ions. The coordination changes to octahedral in the brown protactinium(V) bromide, but is unknown for protactinium(V) iodide. The protactinium coordination in all its tetrahalides is 8, but the arrangement is square antiprismatic in protactinium(IV) fluoride and dodecahedral in the chloride and bromide. Brown-colored protactinium(III) iodide has been reported, where protactinium ions are 8-coordinated in a bicapped trigonal prismatic arrangement.
== Asia == Asian countries are the primary destination for crude oil from the Gulf, with most of it travelling via the Strait of Hormuz. In 2024, around 84 per cent of the crude oil and 83 per cent of LNG passing through the Strait went to Asia; nearly 70 per cent of the oil went to China, India, Japan, and South Korea. Governments and businesses across the region have been imposing measures to reduce the impact of the fuel crisis, and among the worst hit countries in the region include Pakistan, Bangladesh, and Vietnam.
=== Health === In 1996, Morgan was diagnosed with diabetes mellitus and for years has been an alcoholic. Morgan has conceded that many of his own troubles were incorporated within 30 Rock episodes. In early December 2010, Morgan received a kidney transplant necessitated by his diabetes and alcohol use. In August 2023, Morgan responded to a comment about his healthy appearance during an episode of Today with Hoda & Jenna by disclosing that he was using semaglutide. In March 2024, he told Jimmy Fallon that he had "learned to out-eat Ozempic" and "gained 40 lbs," but later clarified that he was joking, saying "Ozempic did great by me and I was glad to use it." On March 17, 2025, while sitting courtside at an NBA basketball game at Madison Square Garden between the New York Knicks and Miami Heat, Morgan experienced an episode of food poisoning, which caused him to vomit onto the basketball court sideline and suffer a bloody nose. He joked on his Instagram post from the hospital saying, "More importantly, the Knicks are now 1-0 when I throw up on the court so maybe I'll have to break it out again in the playoffs."
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.